Total Payments
$27,358
2024 Payments
$2,272
Companies
26
Transactions
85
Medicare Patients
2,467
Medicare Billing
$215,945
Payment Breakdown by Category
Consulting$18,576 (67.9%)
Other$6,925 (25.3%)
Food & Beverage$1,552 (5.7%)
Education$305.27 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $18,576 | 11 | 67.9% |
| Honoraria | $6,925 | 4 | 25.3% |
| Food and Beverage | $1,552 | 65 | 5.7% |
| Education | $305.27 | 5 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ARRAY BIOPHARMA INC | $10,705 | 6 | $0 (2023) |
| Amgen Inc. | $3,858 | 14 | $0 (2023) |
| Sirtex Medical Inc | $2,860 | 3 | $0 (2023) |
| TAIHO ONCOLOGY, INC. | $2,200 | 1 | $0 (2023) |
| Astellas Pharma Global Development | $2,172 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,091 | 3 | $0 (2021) |
| Seagen Inc. | $1,225 | 1 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $900.00 | 1 | $0 (2020) |
| Janssen Biotech, Inc. | $349.93 | 13 | $0 (2021) |
| Incyte Corporation | $146.67 | 4 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,272 | 2 | Astellas Pharma Global Development ($2,172) |
| 2023 | $9,787 | 10 | Amgen Inc. ($2,744) |
| 2022 | $7,846 | 6 | ARRAY BIOPHARMA INC ($6,615) |
| 2021 | $2,245 | 3 | AstraZeneca Pharmaceuticals LP ($2,055) |
| 2020 | $4,127 | 9 | ARRAY BIOPHARMA INC ($2,200) |
| 2019 | $463.69 | 18 | Sirtex Medical Inc ($150.00) |
| 2018 | $321.04 | 18 | Merck Sharp & Dohme Corporation ($45.85) |
| 2017 | $296.17 | 19 | E.R. Squibb & Sons, L.L.C. ($70.63) |
All Payment Transactions
85 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Astellas Pharma Global Development | Vyloy (Drug) | Consulting Fee | Cash or cash equivalent | $2,172.00 | General |
| Category: Oncology | ||||||
| 01/03/2024 | PFIZER INC. | — | Education | In-kind items and services | $99.99 | General |
| 11/15/2023 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $109.60 | General |
| Category: Interventional Oncology | ||||||
| 11/01/2023 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Interventional Oncology | ||||||
| 07/19/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $2,058.00 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $686.00 | General |
| Category: Oncology | ||||||
| 05/05/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Consulting Fee | Cash or cash equivalent | $1,890.00 | General |
| Category: ONCOLOGY | ||||||
| 04/06/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 03/07/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $93.66 | General |
| 02/14/2023 | PFIZER INC. | BOSULIF (Drug) | Education | In-kind items and services | $1.14 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 01/20/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $93.03 | General |
| 01/20/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $55.48 | General |
| Category: Oncology | ||||||
| 12/09/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $1,575.00 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Consulting Fee | Cash or cash equivalent | $1,890.00 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2022 | Seagen Inc. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,225.00 | General |
| Category: Oncology | ||||||
| 11/03/2022 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $6.31 | General |
| 08/19/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $90.00 | General |
| Category: Oncology | ||||||
| 04/01/2021 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.99 | General |
| 02/25/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 12/11/2020 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $2,200.00 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2020 | Janssen Biotech, Inc. | ERLEADA (Drug), BALVERSA | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Oncology | ||||||
| 10/14/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
| 08/12/2020 | Amgen Inc. | Vectibix (Biological) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 359 | 705 | $206,277 | $57,403 |
| 2022 | 8 | 337 | 676 | $186,501 | $55,937 |
| 2021 | 6 | 248 | 484 | $135,890 | $43,267 |
| 2020 | 29 | 1,523 | 2,310 | $222,978 | $59,339 |
Total Patients
2,467
Total Services
4,175
Medicare Billing
$215,945
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 123 | 395 | $114,056 | $31,767 | 27.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 69 | $26,807 | $8,185 | 30.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 89 | 142 | $27,122 | $6,755 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $16,078 | $4,361 | 27.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $8,862 | $2,266 | 25.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $5,387 | $1,700 | 31.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 22 | $4,158 | $1,446 | 34.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $3,808 | $922.43 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 112 | 386 | $106,150 | $31,569 | 29.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 76 | 128 | $24,064 | $6,716 | 27.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $17,424 | $4,932 | 28.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 32 | 37 | $13,690 | $4,714 | 34.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $9,706 | $2,657 | 27.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 35 | 43 | $7,740 | $2,642 | 34.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $4,104 | $1,441 | 35.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 14 | $3,623 | $1,266 | 35.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 80 | 241 | $67,008 | $21,280 | 31.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 59 | 126 | $23,734 | $7,272 | 30.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 38 | 38 | $19,412 | $6,243 | 32.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 28 | 33 | $12,169 | $4,150 | 34.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $9,548 | $2,839 | 29.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 20 | 23 | $4,020 | $1,482 | 36.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 48 | 85 | $13,600 | $13,334 | 98.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 148 | 208 | $31,924 | $11,288 | 35.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 55 | 86 | $21,565 | $7,295 | 33.8% |
About Dr. Raymond Wadlow, MD
Dr. Raymond Wadlow, MD is a Internal Medicine healthcare provider based in Fairfax, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548370612.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raymond Wadlow, MD has received a total of $27,358 in payments from pharmaceutical and medical device companies, with $2,272 received in 2024. These payments were reported across 85 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($18,576).
As a Medicare-enrolled provider, Wadlow has provided services to 2,467 Medicare beneficiaries, totaling 4,175 services with total Medicare billing of $215,945. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Fairfax, VA
- Active Since 08/30/2006
- Last Updated 02/28/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1548370612
Products in Payments
- BRAFTOVI (Drug) $10,705
- SIR-Spheres Microspheres (Device) $2,860
- LUMAKRAS (Drug) $2,744
- LONSURF (Drug) $2,200
- Vyloy (Drug) $2,172
- TUKYSA (Drug) $1,225
- Vectibix (Biological) $916.24
- Stivarga (Drug) $900.00
- DARZALEX (Biological) $180.39
- IMBRUVICA (Drug) $126.70
- OPDIVO (Biological) $102.98
- KEYTRUDA (Biological) $96.24
- Neulasta (Biological) $80.52
- KANJINTI (Biological) $55.74
- Cologuard Collection Kit (Device) $55.48
- JAKAFI (Drug) $46.68
- ERLEADA (Drug) $42.84
- Avastin (Biological) $40.39
- TAGRISSO (Drug) $36.43
- Rubraca (Drug) $29.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Fairfax
Samim Enayat, Md, MD
Internal Medicine — Payments: $437,610
Internal Medicine $437,610
Brett Atwater, M.d, M.D
Internal Medicine — Payments: $355,531
Internal Medicine $355,531
Kathleen Harnden, M.d, M.D
Internal Medicine — Payments: $173,063
Internal Medicine $173,063
Dr. Daniel Kim, M.d., M.b.a, M.D., M.B.A
Internal Medicine — Payments: $124,814
Internal Medicine $124,814
Dr. Reza Zonozi, M.d, M.D
Internal Medicine — Payments: $118,319
Internal Medicine $118,319
Dr. Elizabeth Held, M.d, M.D
Internal Medicine — Payments: $84,557
Internal Medicine $84,557